We report the role of relative lymphocyte count ( RLC ) as a potential biomarker with prognostic impact for catumaxomab efficacy and overall survival ( OS ) based on a post hoc analysis of the pivotal phase II/III study of intraperitoneal catumaxomab treatment of malignant ascites .